OTC · TRVN
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 7:58 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
TRVN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning TRVN.
TRVN research
Company profile and research snapshot.
TREVENA INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Neutral | — |
| May 16, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 2, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2024 | HC Wainwright & Co. | Buy | — |
| May 17, 2023 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 7, 2024
Trevena, Inc. reported a net loss of $4.9 million for Q3 2024, down from $7.9 million in Q3 2023. The company is exploring strategic alternatives, including a potential sale or discontinuation of its OLINVYK product, and has implemented cost-cutting measures, including the termination of several senior executives.
GlobeNewswire Inc. · Jun 20, 2024
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
GlobeNewswire Inc. · Dec 28, 2023
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million (the “private placement”).
GlobeNewswire Inc. · Dec 27, 2023
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the “private placement”).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRVN.
